-
One article to understand the competitive landscape of the domestic biosimilar drug market
Time of Update: 2022-08-11
1 Domestic biosimilars Ushering in a competitive landscape of blooming flowers At present, there are six biosimilars listed by domestic pharmaceutical companies: bevacizumab, adalimumab, trastuzumab, rituximab, denosumab and infliximab (see Table 1) .
-
The National Medical Insurance Administration issued a notice that the new coronavirus nucleic acid test and antigen test will further reduce the price
Time of Update: 2022-08-11
Today, the National Medical Insurance Administration issued the "Notice of the Medical Rescue Team of the Joint Prevention and Control Mechanism of the New Coronavirus Pneumonia Epidemic by the Offic
-
The supervision of the retail pharmacy market is becoming more and more strict, and compliance has become a top priority
Time of Update: 2022-08-11
Recently, the National Medical Insurance Bureau exposed 10 typical cases of illegal violations by designated retail pharmacies, including the sale of non-medical insurance drugs or other commodities f
-
"Draft for Comments", new chapters for drug marketing authorization holders, etc.
Time of Update: 2022-08-11
The "Draft for Comments" puts forward the basic requirements for drug management : drug development, production, operation, use, and supervision and management activities should follow scientific requirements and ethical guidelines, comprehensively prevent and control risks, implement responsibilities, promote system construction, and improve management capabilities.
-
The competition for the inhalant market among pharmaceutical companies is fierce, and the industry will be reshuffled
Time of Update: 2022-08-11
Data shows that in 2021, the sales of levalbuterol hydrochloride atomized inhalation solution in public medical institutions in China will increase by more than 3,209% year-on-year, or about 200 million yuan .
-
The promotion meeting of the special rectification work of drug safety was held
Time of Update: 2022-08-10
On May 30, the State Food and Drug Administration held a promotion meeting for the special rectification of drug safety, summed up the work of the special rectification of drug safety in the previous stage , exchanged and shared the experience of various places, and promoted the whole system to carry out the special rectification of drug safety in depth .
-
TOP12 global rare disease drugs in 2021: K drug sales of US$17.18 billion, BMS two blockbuster drugs ranked in the top three
Time of Update: 2022-08-10
12Jakafi In late 2011, Jakafi became the first JAK inhibitor approved by the FDA for the treatment of the bone marrow disease myelofibrosis .
The drug's active ingredient, lenalidomide, is a new-generation derivative of thalidomide with immunomodulatory, anti-angiogenic and anti-tumor properties Revlimid is a blockbuster immunomodulator obtained after Bristol-Myers Squibb acquired Celgene.
-
The back waves of the children's medicine potential track are strong
Time of Update: 2022-08-10
On the one hand, the information of children's drug labeling needs to be supported by scientific research evidence ; Some company leaders believe that "children's clinical research is the current bottleneck restricting the development of children's medicine in China .
-
Ten consecutive boards, daily limit tide!
Time of Update: 2022-08-10
Zhongsheng Pharmaceutical On the evening of May 11, Zhongsheng Pharmaceutical issued an announcement that the clinical trial registration application of Zhongsheng Ruichuang oral anti-new coronavirus 3CL protease inhibitor, a class of innovative drugs, RAY1216 tablets, was accepted by the State Food and Drug Administration.
-
The development of the Chinese medicine industry continues to improve, and the export market of Chinese herbal medicines and Chinese patent medicines is constantly expanding
Time of Update: 2022-08-10
2% For example, according to customs statistics, in the first quarter of this year, the total import and export value of Chinese medicinal materials and Chinese patent medicines in Bozhou City was 140 million yuan, a decrease of 0.
-
Illustration of network security and informatization construction of drug supervision "14th Five-Year Plan"
Time of Update: 2022-08-10
The "Plan" clarifies: implement the drug supervision concepts of risk governance, responsibility governance, whole-process governance, and smart governance, adhere to systematic thinking, make full use of the results of regulatory scientific research, innovate regulatory methods and methods, improve regulatory systems and mechanisms, and promote the integration of information technology and business development.
-
TIGIT research and development has been setback!
Time of Update: 2022-08-10
The leading pharmaceutical companies are obviously unwilling to miss the next market opportunity in the "post-PD-1 era", and are scrambling to expand the "circle of friends" by waving banknotes ": In October 2020, AstraZeneca announced a collaboration with Arcus Biosciences to initiate a registrational Phase 3 clinical trial evaluating Arcus' investigational anti-TIGIT antibody domvanalimab (AB154) in combination with the PD-L1 inhibitor Imfinzi (durvalumab) in Africa.
-
The sixth batch of collection results was carried out in many places, and tens of millions of diabetic patients will use affordable insulin
Time of Update: 2022-08-10
[Pharmaceutical Network Industry News] At the end of April, the National Medical Insurance Administration and other two departments issued the "Notice on Improving the National Organization of Drugs (Insulin Special) Centralized Procurement and Use of Supporting Measures", requiring the selected products of insulin centralized procurement to be selected in each province.
-
The State Pharmacopoeia Commission solicits proposals for the implementation of "green environmental protection" pharmaceutical excipient standards
Time of Update: 2022-08-10
On May 6, the official website of the State Pharmacopoeia Committee issued a notice to solicit suggestions on the implementation of "green environmental protection" pharmaceutical excipient standards
-
Which pharmaceutical company lays off employees?
Time of Update: 2022-08-10
Among them, three foreign-funded pharmaceutical companies, Arcadia Healthcare, AlerisLife, and Brookdale Senior Care, will lay off more than 10,000 employees, which will decrease respectively.
Among them, three foreign-funded pharmaceutical companies, Arcadia Healthcare, AlerisLife, and Brookdale Senior Care, will lay off more than 10,000 employees, which will decrease respectively.
-
More than half of the traditional Chinese medicine companies are profitable, and the net profit of 5 companies has increased by more than 100%
Time of Update: 2022-08-10
009 billion yuan, a year-on-year increase of 343% Conba: Net profit rose by more than 343% According to Conba's annual report, in 2021, it will achieve operating income of 6.
-
The national insulin special centralized procurement landed in Qinghai, an average drop of 48%
Time of Update: 2022-08-10
89 yuan per vial, depending on the patient It is estimated that using 6 sticks per month can save about 4,200 yuan in medication costs for a year, and the average daily cost is as low as less than 4 yuan Eli Lilly's Protamine Zinc Recombinant Insulin Lispro Mixed Injection (25R), 3ml: 300 units (pre-filled), which has the largest drop in centralized procurement, has dropped from an average of 80.
-
Professional perspective, online analysis!
Time of Update: 2022-08-10
For the analysis technology and solutions of pollutants, scholars and friends are welcome to participate in this online exchange activity At this stage, where is the research on environmental organic pollutants?
-
Shanghai: Biopharmaceutical Industry Fully "Resurrected" →
Time of Update: 2022-08-10
Since the epidemic, quite a number of Shanghai biopharmaceutical companies have implemented closed-loop production, making every effort to ensure the production and supply of anti-tumor and other major disease drugs and devices .
-
The performance of pharmaceutical distribution companies shows an upward trend, and the revenue of 4 companies exceeds 50 billion
Time of Update: 2022-08-10
Among them, the medical device distribution segment achieved revenue of 108 billion yuan, a year-on-year increase of 21%; retail sales reached 29 billion yuan, an increase of 20% .
